Who is sponsoring NCT03697031?

NCT03697031 is sponsored by Ferring Pharmaceuticals.

What drugs are being tested in NCT03697031?

Interventions in NCT03697031: Follitropin Delta.

What condition does NCT03697031 study?

NCT03697031 studies Controlled Ovarian Stimulation.

Is NCT03697031 still recruiting?

NCT03697031 is currently terminated. Last updated 12 December 2023.

Last reviewed 2023-12-12 · How we verify

NCT03697031

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®

Terminated Last updated 12 December 2023

What this trial tests

trial testing Follitropin Delta in Controlled Ovarian Stimulation in 362 participants. Terminated before completion.

Timeline

1 September 2018

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Ferring Pharmaceuticals
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	362
Start date	1 September 2018
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Denmark

Drugs / interventions tested

Follitropin Delta — full drug profile →

Conditions studied

Controlled Ovarian Stimulation — all drugs for Controlled Ovarian Stimulation →

Sponsor

Ferring Pharmaceuticals — full company profile →

Who can join

Adults 18 to 45, female only, with Controlled Ovarian Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study is to examine the development and appearance of embryos before and after freezing following a single controlled ovarian stimulation cycle using REKOVELLE® (follitropin delta) as the recombinant follicular stimulating hormone (rFSH) for controlled ovarian stimulation. The primary objective of the study is to examine how specific factors of embryo development or appearance are related to the chance of becoming pregnant. The ovarian stimulation protocol with REKOVELLE®, a new rFSH prescribed for ovarian stimulation, is individualised with a dosing regimen that is based on two parameters: the body weight and the level of a hormone, the anti-Müllerian hormone, (AMH), a parameter used to predict how the ovaries will respond to the ovarian stimulation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pre-Vitrification and Post-Warming Variables of Vitrified-Warmed Blastocysts That Are Predictable for Implantation.
Gabrielsen A, Iversen LH, Fedder J, Eskildsen TV, et al · · 2023 · cited 4× · PMID 37835035 · DOI 10.3390/jcm12196389

Verify or expand the search:

Other trials of Follitropin Delta

Trials testing the same drug.

NCT04503707 — Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Inj · completed
NCT04150861 — Rekovelle PK Trial in Chinese Women · Phase 1 · completed
NCT03393780 — Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic S · completed

Other Ferring Pharmaceuticals trials

Trials by the same sponsor.

NCT07152730 — A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump · Phase 1 · withdrawn
NCT07029451 — To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt · recruiting
NCT06668493 — Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis · Phase 1, PHASE2 · recruiting
NCT06545955 — A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in · Phase 3 · recruiting
NCT06510374 — Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Can · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03697031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ferring Pharmaceuticals
Last refreshed: 12 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03697031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing